# Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
Canonical URL: https://biopharmsignal.com/news/REGN/next-generation-of-scientific-leaders-awarded-more-than-7-million-at-the-2026-regeneron-international-science-and-engineering-fair
Ticker: REGN
Company: Regeneron Pharmaceuticals
Source: Regeneron Pharmaceuticals
Published: 2026-05-15 18:09 EST
Original Source URL: https://investor.regeneron.com
## Summary

Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition. TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

## Article Body
Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition. TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
## Recent Company News
- 2026-06-04 11:00 EST — [Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO](https://biopharmsignal.com/news/REGN/regeneron-to-highlight-progress-across-its-metabolic-disease-ophthalmology-and-rare-disease-pipelines-at-ada-and-endo) — Source: Regeneron Pharmaceuticals
- 2026-05-28 20:00 EST — [Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak](https://biopharmsignal.com/news/REGN/regeneron-s-ebola-antibody-recommended-by-world-health-organization-for-investigational-use-in-response-to-current-bundibugyo-ebolavirus-outbreak) — Source: Regeneron Pharmaceuticals
- 2026-05-22 11:00 EST — [Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss](https://biopharmsignal.com/news/REGN/otarmenitm-lunsotogene-parvec-receives-ema-filing-acceptance-for-genetic-hearing-loss) — Source: Regeneron Pharmaceuticals
- 2026-05-21 21:01 EST — [Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis](https://biopharmsignal.com/news/REGN/lynozyficr-linvoseltamab-monotherapy-demonstrates-deep-and-rapid-responses-in-all-treated-patients-with-second-line-plus-systemic-amyloid-light-chain-amyloidosis) — Source: Regeneron Pharmaceuticals
- 2026-05-18 11:00 EST — [Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas](https://biopharmsignal.com/news/REGN/regeneron-announces-strategic-collaboration-with-parabilis-medicines-to-advance-novel-antibody-helicontm-conjugates-across-multiple-therapeutic-areas) — Source: Regeneron Pharmaceuticals
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)